SCHEMBL30608458

SCHEMBL30608458

[2H]c1c([2H])c([2H])c2c(-c3ccc4oc5ccccc5c4c3)c3c([2H])c([2H])c([2H])c([2H])c3cc2c1[2H]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ HPGD P15428 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ AHR P35869 2/20 0.39
▸ CASP3 P42574 1/20 0.36
▸ SENP7 Q9BQF6 1/20 0.36
▸ SENP6 Q9GZR1 1/20 0.36
▸ CHEK2 O96017 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ HSP90AB1 P08238 1/20 0.36
▸ PLA2G2A P14555 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31174235 0.85 MAPT (0.42) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL29990681 0.84 MAPT (0.44) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL18842449 0.81 MAPT (0.41) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL23406342 0.81 ALOX5 (0.51) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL30542933 0.81 ALOX5 (0.51) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL16363434 0.81 MAPT (0.57) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL21450734 0.81 MAPT (0.57) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL31018375 0.79 NPC1 (0.35) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL21450766 0.79 MAPT (0.55) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL21450760 0.79 MAPT (0.55) MAPTKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002312-A1 METHOD FOR PREPARING DEUTERATED ANTHRACENE COMPOUND, REACTION COMPOSITION, DEUTERATED ANTHRACENE COMPOUND AND COMPOSITION LG CHEM, LTD. (KR) 2024-01-04 — — US disclosed
CN-116547255-A Methods, reaction compositions, deuterated anthracene compounds, and compositions for preparing deuterated anthracene compounds 株式会社LG化学 2023-08-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002312-A1 METHOD FOR PREPARING DEUTERATED ANTHRACENE COMPOUND, REACTION COMPOSITION, DEUTERATED ANTHRACENE COMPOUND AND COMPOSITION AHR, AR, CYP1A1 MAPT 4446/4885KDM4E 3280/4885ALDH1A1 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback